Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook
Also Strikes Deal With AZ For Pulmicort Respules In Colombia
Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.
You may also be interested in...
Glenmark Builds US OTC Lineup In Wockhardt Deal
Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.
Glenmark Bolsters US OTC Portfolio With Wockhardt Products
Glenmark has moved to bolster its over-the-counter business in the US by acquiring a portfolio of approved generic OTC products from Wockhardt.
Glenmark Chief: Running A Facility In The US Has Been A Struggle
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.